Last reviewed · How we verify
darunavir/ritonavir QD + raltegravir BID
darunavir/ritonavir QD + raltegravir BID is a Protease inhibitor and integrase strand transfer inhibitor Small molecule drug developed by ANRS, Emerging Infectious Diseases. It is currently in Phase 3 development for Treatment of HIV-1 infection.
Darunavir/ritonavir QD is a protease inhibitor that blocks HIV replication, while raltegravir BID is an integrase strand transfer inhibitor that also blocks HIV replication.
Darunavir/ritonavir QD is a protease inhibitor that blocks HIV replication, while raltegravir BID is an integrase strand transfer inhibitor that also blocks HIV replication. Used for Treatment of HIV-1 infection.
At a glance
| Generic name | darunavir/ritonavir QD + raltegravir BID |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Protease inhibitor and integrase strand transfer inhibitor |
| Target | HIV protease and HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Darunavir/ritonavir QD works by inhibiting the protease enzyme of the HIV virus, preventing it from replicating. Raltegravir BID works by inhibiting the integrase enzyme of the HIV virus, also preventing it from replicating. This combination of drugs is used to treat HIV infection.
Approved indications
- Treatment of HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
- Dizziness
- Insomnia
- Rash
- Anemia
- Neutropenia
Key clinical trials
- RESIST-2: 2nd-line ART for HIV-2 Infection (NA)
- Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.
- Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults (PHASE2)
- Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir (NA)
- Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) (NA)
- Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) (PHASE3)
- Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects (PHASE3)
- Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- darunavir/ritonavir QD + raltegravir BID CI brief — competitive landscape report
- darunavir/ritonavir QD + raltegravir BID updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI
Frequently asked questions about darunavir/ritonavir QD + raltegravir BID
What is darunavir/ritonavir QD + raltegravir BID?
How does darunavir/ritonavir QD + raltegravir BID work?
What is darunavir/ritonavir QD + raltegravir BID used for?
Who makes darunavir/ritonavir QD + raltegravir BID?
What drug class is darunavir/ritonavir QD + raltegravir BID in?
What development phase is darunavir/ritonavir QD + raltegravir BID in?
What are the side effects of darunavir/ritonavir QD + raltegravir BID?
What does darunavir/ritonavir QD + raltegravir BID target?
Related
- Drug class: All Protease inhibitor and integrase strand transfer inhibitor drugs
- Target: All drugs targeting HIV protease and HIV integrase
- Manufacturer: ANRS, Emerging Infectious Diseases — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of HIV-1 infection
- Compare: darunavir/ritonavir QD + raltegravir BID vs similar drugs
- Pricing: darunavir/ritonavir QD + raltegravir BID cost, discount & access